MedTrace Logo

CCRO044: Quality of Life Assessments Associated With a Physician Communication Intervention for Prostate Cancer Patients

NCT03780023 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5

Last updated 2020-10-28

No results posted yet for this study

Summary

A generic cancer health-related quality of life measure will be used to assess the impact of the patient-specific radiation therapy plan review using the European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-C30. Patient psychosocial adjustment will be assessed by the Memorial Anxiety Scale for prostate cancer and the EORTC QLQ-C30 subdomain. Physician communication will be assessed with the UC Davis Physician Communication adapted from the Cologne Patient Questionnaire.

The study will characterize the above health-related quality of life (HRQL) scores (EORTC QLQ C-30, the Memorial Anxiety Scale, and the UC Davis Physician Communication) prior to initiation of radiation (baseline), during the first week of treatment, at the end of radiation treatment (6-8 weeks following initiation of treatment), and 12 months after treatment ends.

Conditions

  • Prostate Adenocarcinoma

Interventions

OTHER

Questionnaire

All patients will receive three questionnaires at four different time points during their radiation treatment. The time points are 1) before treatment, 2) during the first week of treatment, 3) at the end of treatment (6-8 weeks after treatment begins), and 4) one year after treatment ends.

Sponsors & Collaborators

  • University of California, Davis

    lead OTHER

Principal Investigators

  • Richard K Valicenti, MD · University of California, Davis

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-17
Primary Completion
2020-05-04
Completion
2020-05-04

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03780023 on ClinicalTrials.gov